TABLE 6 PBPK model–predicted pharmacokinetic parameters of crizotinib in healthy subjects following 28-day multiple oral administration of crizotinib with and without coadministration of ketoconazole or rifampin
Data are expressed as geometric mean with percent coefficient of variation (CV%) in parentheses (n = 15 per group × 6 groups). Dose levels were crizotinib 150 mg twice daily and ketoconazole 200 mg twice daily in the crizotinib-ketoconazole interaction and crizotinib 250 mg twice daily and rifampin 600 mg once daily in the crizotinib-rifampin interaction.